化膿性汗腺炎（HS）市場 - 市場の洞察、疫学、市場予測：2032年

米国の化膿性汗腺炎（HS）の市場規模は、2022年に約10億米ドルとなりました。同市場は予測期間中（2023年～2032年）にさらに拡大すると予測されています。欧州4ヶ国と英国市場においては、ドイツが最大の市場シェアを有し、スペインが最小のシェアとなっています。

当レポートでは、主要7ヶ国における化膿性汗腺炎（HS）市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 主な洞察

第2章 レポートのイントロダクション

第3章 化膿性汗腺炎市場概要

• 市場シェア（%）化膿性汗腺炎の分布、治療法別（2019年）
• 市場シェア（%）化膿性汗腺炎の分布、治療法別（2032年）

第4章 化膿性汗腺炎のエグゼクティブサマリー

第5章 主な事象

第6章 疫学と市場調査手法

第7章 疾患の概要：化膿性汗腺炎

• イントロダクション
• 化膿性汗腺炎の原因と症状
• 化膿性汗腺炎の分類と重症度評価
• 化膿性汗腺炎の病態生理
• 化膿性汗腺炎の遺伝的基盤
• 化膿性汗腺炎の診断
• 化膿性汗腺炎のバイオマーカー
• 危険因子と合併症
• 合併症

第8章 治療とガイドライン

第9章 疫学と患者数

• 仮定と根拠：主要7ヶ国
• 主な調査結果
• 主要7ヶ国における化膿性汗腺炎の罹患総数
• 主要7ヶ国における化膿性汗腺炎の診断済み罹患総数
• 米国
• 欧州4ヶ国と英国
• 日本

第10章 化膿性汗腺炎の患者動向

第11章 化膿性汗腺炎の臨床試験における主要なエンドポイント

第12章 上市済み薬剤

第13章 新薬

第14章 化膿性汗腺炎：主要7ヶ国市場分析

• 主な調査結果
• 市場の見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 主要7ヶ国の化膿性汗腺炎市場全体の規模
• 米国の市場規模
• 欧州4ヶ国と英国の市場規模
• 日本の市場規模

第15章 市場アクセスと償還

第16章 アンメットニーズ

第17章 SWOT分析

第18章 KOL の見解

第19章 付録

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

List of Tables

• Table 1: Summary of hidradenitis suppurativa Market, and Epidemiology (2019-2032)
• Table 2: Hurley Staging System
• Table 3: Modified Sartorius Score of Hidradenitis Suppurativa
• Table 4: Physician Global Assessment of Hidradenitis Suppurativa
• Table 5: Specific Severity Index of Hidradenitis Suppurativa (HSSI)
• Table 6: Differential Diagnosis of Hidradenitis Suppurativa
• Table 7: Recommendations for Medical Treatment of Hidradenitis Suppurativa
• Table 8: Recommendations for Surgical Treatment of Hidradenitis Suppurativa
• Table 9: Total Prevalent Cases of Hidradenitis Suppurativa in the 7MM, in thousands (2019-2032)
• Table 10: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the 7MM, in thousands (2019-2032)
• Table 11: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Table 12: Gender-Specific Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Table 13: Age-specific Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Table 14: Stage-specific Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Table 15: Treated Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Table 16: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Table 17: Gender-specific Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Table 18: Age-specific Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Table 19: Stage-specific Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Table 20: Treated Prevalent Cases of hidradenitis suppurativa in the EU4 and the UK (2019-2032)
• Table 21: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Table 22: Gender-specific Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Table 23: Age-specific Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Table 24: Stage-specific Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Table 25: Treated Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Table 26: Key Cross of Emerging Therapies
• Table 27: COSENTYX (secukinumab), Clinical Trial Description, 2023
• Table 28: BIMZELX (bimekizumab), Clinical Trial Description, 2023
• Table 29: Povorcitinib (INCB054707), Clinical Trial Description, 2023
• Table 30: Ruxolitinib 1.5% cream, Clinical Trial Description, 2023
• Table 31: CFZ533, LYS006, LOU064, and MAS825 Clinical Trial Description, 2023
• Table 32: Lutikizumab (ABT-981), Clinical Trial Description, 2023
• Table 33: Zunsemetinib, Clinical Trial Description, 2023
• Table 34: Spesolimab, Clinical Trial Description, 2023
• Table 35: Orismilast, Clinical Trial Description, 2023
• Table 36: RINVOQ (upadacitinib), Clinical Trial Description, 2023
• Table 37: Izokibep, Clinical Trial Description, 2023
• Table 38: Brepocitinib (PF-06700841), Clinical Trial Description, 2023
• Table 39: Sonelokimab, Clinical Trial Description, 2023
• Table 40: Eltrekibart (LY3041658), Clinical Trial Description, 2023
• Table 41: Off-label Therapies Used in hidradenitis suppurativa Treatment
• Table 42: Key Market Forecast Assumptions for COSENTYX
• Table 43: Key Market Forecast Assumptions for BIMZELX (bimekizumab)
• Table 44: Key Market Forecast Assumptions for Povorcitinib
• Table 45: Key Market Forecast Assumptions for Orismilast
• Table 46: Key Market Forecast Assumptions for RINVOQ
• Table 47: Key Market Forecast Assumptions for Izokibep
• Table 48: Key Market Forecast Assumptions for Spesolimab
• Table 49: Key Market Forecast Assumptions for Sonelokimab
• Table 50: Total Market Size of Hidradenitis Suppurativa in the 7MM, USD million (2019-2032)
• Table 51: Market Size of Hidradenitis Suppurativa in the US, USD million (2019-2032)
• Table 52: Market Size of Hidradenitis Suppurativa by Therapies in the US, USD million (2019-2032)
• Table 53: Market Size of Hidradenitis Suppurativa in EU4 and the UK USD million (2019-2032)
• Table 54: Market Size of Hidradenitis Suppurativa by Therapies in Germany, USD million (2019-2032)
• Table 55: Market Size of Hidradenitis Suppurativa by Therapies in France, USD million (2019-2032)
• Table 56: Market Size of Hidradenitis Suppurativa by Therapies in Italy, USD million (2019-2032)
• Table 57: Market Size of Hidradenitis Suppurativa by Therapies in Spain, USD million (2019-2032)
• Table 58: Market Size of Hidradenitis Suppurativa by Therapies in the UK, USD million (2019-2032)
• Table 59: Market Size of Hidradenitis Suppurativa by Therapies in EU4 and the UK, USD million (2019-2032)
• Table 60: Market Size of Hidradenitis Suppurativa in Japan USD million (2019-2032)
• Table 61: Market Size of Hidradenitis Suppurativa by Therapies in Japan, USD million (2019-2032)
• Table 62: Market Access and Reimbursement Scenario of Adalimumab Biosimilars in France
• Table 63: Co-payment in the European Countries

List of Figures

• Figure 1: Disease Burden in the Patient with hidradenitis suppurativa
• Figure 2: Stages of Hidradenitis Suppurativa
• Figure 3: Pathophysiology of hidradenitis suppurativa
• Figure 4: An approach to the Diagnosis of Hidradenitis suppurativa
• Figure 5: Risk Factors of hidradenitis suppurativa
• Figure 6: Comorbidities in Hidradenitis Suppurativa
• Figure 7: Treatment Options for Hidradenitis Suppurativa
• Figure 8: Treatment Algorithm for Hidradenitis Suppurativa
• Figure 9: Total Prevalent Cases of Hidradenitis Suppurativa in the 7MM (2019-2032)
• Figure 10: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the 7MM (2019-2032)
• Figure 11: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Figure 12: Gender-Specific Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Figure 13: Age-specific Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Figure 14: Stage-specific Prevalent cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Figure 15: Treated Prevalent Cases of Hidradenitis Suppurativa in the United States (2019-2032)
• Figure 16: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Figure 17: Gender-specific Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Figure 18: Age-specific Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Figure 19: Stage-specific Cases of Hidradenitis Suppurativa in EU4 and the UK (2019-2032)
• Figure 20: Treated Prevalent Cases of Hidradenitis Suppurativa in the EU4 and the UK (2019-2032)
• Figure 21: Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Figure 22: Gender-specific Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Figure 23: Age-specific Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Figure 24: Stage-specific Prevalent cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Figure 25: Treated Prevalent Cases of Hidradenitis Suppurativa in Japan (2019-2032)
• Figure 26: Requirements of HiSCR
• Figure 27: Window of opportunity in HS
• Figure 28: Market Size of Hidradenitis Suppurativa in the 7MM, USD million (2019-2032)
• Figure 29: Market Size of Hidradenitis Suppurativa in the US, USD million (2019-2032)
• Figure 30: Market Size of Hidradenitis Suppurativa by Therapies in the US (2019-2032)
• Figure 31: Market Size of Hidradenitis Suppurativa in EU4 and the UK, USD million (2019-2032)
• Figure 32: Market Size of Hidradenitis Suppurativa by Therapies in EU4 and the UK, USD million (2019-2032)
• Figure 33: Market Size of Hidradenitis Suppurativa in Japan USD million (2019-2032)
• Figure 34: Market Size of Hidradenitis Suppurativa by Therapies in Japan USD million (2019-2032)

DelveInsight's " Hidradenitis Suppurativa - Market Insights, Epidemiology and Market Forecast-2032" report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.

The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Hidradenitis Suppurativa market size from 2019 to 2032. The report also covers current Hidradenitis Suppurativa treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Hidradenitis Suppurativa Disease Understanding and Treatment Algorithm

Hidradenitis Suppurativa Overview

According to the National Organization of Rare Disorders, Hidradenitis suppurativa is a chronic condition characterized by swollen, painful lesions, occurring in the armpit, groin, anal and breast regions. It is a painful and long-term skin condition causing abscesses and scarring on the skin. Affected patients may present with acute abscesses, but the condition often progresses to a chronic state with persistent pain, sinus tract fistula formation, and scarring. Although foreign body type granulomas are a common finding in Hidradenitis suppurativa, the presence of discrete epithelioid granulomas in the dermis away from the site of active inflammation is unusual and should alert the pathologist to the possibility of a systemic granulomatous disease like Crohn's disease (CD) or sarcoidosis. The longstanding disease can result in fibrosis, dermal contractures, significant scarring, the formation of fistulae, and rarely malignant transformation to squamous cell carcinoma.

It is a difficult condition to face physically as well as mentally the individual can manage the condition by preventing breakouts, draining the lesions, and in some cases, using skin grafts to repair damaged areas.

There is significant inter-individual variability regarding the site of the disease, the type of lesions presents, and the associated systemic response (general malaise, arthralgia, and rise in inflammatory markers) during disease flares. It affects females about three times more often than males. The condition typically becomes apparent during puberty but almost never after the age of about 40 years. Many things can trigger flare-ups of this disease including menstruation for women, weight gain, stress, hormonal changes, heat, and perspiration. In some cases, early symptoms, such as itching or discomfort, may precede the condition's characteristic manifestations.

Hidradenitis Suppurativa Diagnosis

The diagnosis is primarily clinical, based on symptoms reported by the patient and signs observed by the physician. No pathognomonic test exists, and biopsy is rarely required, especially in well-developed lesions.

Primary Diagnosis of Hidradenitis suppurativa involves the identification of the disease and assessment of its comorbidities. Fulfillment of three criteria are necessary for the diagnosis of Hidradenitis suppurativa:

• Typical lesions: deep-seated, painful nodules
• Characteristic distribution: Typical anatomical predilection (i.e. axillae, groins, perineal and perianal regions, buttocks, infra-mammary and inter-mammary folds)
• Recurrence: Chronicity and recurrence of lesions

Hidradenitis suppurativa is usually associated with depression and severe overall impairment of quality of life (QoL), exceeding other skin disorders heavily impacting Quality of life such as psoriasis, atopic dermatitis, alopecia, and acne. Hidradenitis suppurativa may restrict simple movements, interfere with routine daily activities, be disfigured because of the wound healing and scarring process, and limit the ability to work. Pain is reported as the most significant factor contributing to the impairment of quality of life in patients with Hidradenitis suppurativa, although malodorous and staining secretions also contribute to poor self-perception, embarrassment, stunted social life, and problems with interpersonal relationships. A plethora of comorbidities including inflammatory bowel diseases, spondyloarthropathies, obesity, and metabolic syndrome, may be associated with Hidradenitis suppurativa, increasing the disease burden. Therefore, the availability of disease severity assessment tools that might accurately evaluate both clinical picture and patients' discomfort is important for the management of patients with Hidradenitis suppurativa and for driving the therapeutic strategy.

There are multiple assessment tools or questionnaires used for evaluating Hidradenitis suppurativa severity. Some are specifically designed for Hidradenitis suppurativa, such as the Hurley staging classification, the modified Sartorius score, the Hidradenitis Suppurativa Clinical Response (HiSCR), the Hidradenitis Suppurativa-Physician Global Assessment (HS-PGA), and the Hidradenitis Suppurativa Severity Index (HSSI). The Hurley staging and the modified Sartorius score are the most commonly used assessment tools in both trial setting and real-life practice.

Hidradenitis Suppurativa Treatment

A clinically relevant staging and disease severity assessment is essential for the development of evidence-based treatments. There are several scoring systems for the assessment of disease severity of Hidradenitis suppurativa, including Hurley staging, Physician's Global Assessment (PGA), the modified Sartorius score (MSS), and Hidradenitis suppurativa Severity Index (HSSI).

In 1989, a severity classification was first proposed by Hurley. Fortunately, Stage I disease is the most common, while Stage II occurs in more than one-fourth of patients, and few cases of Hidradenitis suppurativa patients have Stage III. The Hurley staging system is the most widely used Hidradenitis suppurativa classification scale in routine clinical practice in three severity groups, but the classification has limitations. The Hurley classification is a not very quantitative one, consisting of only three stages and based on rather static disease characteristics such as scarring and fistulas.

Hence, it is not suitable for monitoring the efficacy of interventions in clinical trials. A more detailed and dynamic Hidradenitis suppurativa severity score was created by Sartorius et al. and was later modified and validated. The main parameter in the modified Sartorius score is the counting of individual nodules and fistulas. This modified Sartorius score is difficult to use and its usability is limited especially in severe cases in which lesions become confluent.

Based upon the published guidelines for hidradenitis suppurativa developed by the Guidelines Subcommittee of the European Dermatology Forum, a detailed review of all therapies was conducted. All therapeutic aspects of the treatment included in the guidelines were reviewed. A category of evidence and strength of recommendation was developed for the first line of therapy, including topical clindamycin, oral clindamycin/rifampicin, tetracycline, and subcutaneous adalimumab. A similar approach was taken for the second-line therapies, including zinc gluconate, resorcinol, intralesional corticosteroids, infliximab, acitretin, and etretinate. Third-line therapies included colchicine, botulinum toxin, isotretinoin, dapsone, cyclosporine, and hormones.

Surgical evaluated therapies included individual lesions excision, total excision of lesions surrounding hair-bearing skin, secondary intention healing, and primary closure, reconstructive with skin grafting and NPWT reconstruction with flap, deroofing, carbon dioxide laser therapy, laser therapy, and intense pulsed light.

Hidradenitis Suppurativa Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total diagnosed prevalent cases of Hidradenitis suppurativa, Gender-specific prevalent cases of Hidradenitis suppurativa, Age-specific prevalent cases of Hidradenitis suppurativa, Stage-specific cases of Hidradenitis suppurativa, in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the Hidradenitis Suppurativa epidemiology in the 7MM

Country Wise- Hidradenitis Suppurativa Epidemiology

• The epidemiology segment also provides the Hidradenitis Suppurativa epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The total diagnosed prevalent cases of Hidradenitis Suppurativa in the 7MM comprised of approximately 1,200,000 cases in 2022 and are projected to increase during the forecast period.
• The total diagnosed prevalent cases of Hidradenitis Suppurativa in the United States are approximately 600,000 in 2022.
• The United States contributed to the largest prevalent cases of Hidradenitis Suppurativa, in the 7MM in 2022.
• Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa cases, whereas Spain accounted for the lowest number of cases in 2022.
• In Japan, the total diagnosed prevalent cases of Hidradenitis Suppurativa were approximately 46,000 in 2022, these cases are anticipated to increase during the forecast period.
• In the US and EU Hidradenitis suppurativa is more common in females than males, affecting approximately 148,000 males and 445,000 females in the US in 2022.

Hidradenitis Suppurativa Drug Chapters

The drug chapter segment of the Hidradenitis Suppurativa report encloses a detailed analysis of Hidradenitis Suppurativa marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hidradenitis Suppurativa clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

HUMIRA (adalimumab): AbbVie

HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). This drug was created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1: kappa constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps.

Note: Detailed Current therapies assessment will be provided in the full report of Hidradenitis suppurativa

Emerging Drugs

COSENTYX (secukinumab): Novartis Pharmaceuticals

COSENTYX (secukinumab), marketed by Novartis is an IL-17A monoclonal antibody that selectively binds to IL-17A and inhibits Interleukin-17A, and IL-17 promotes neutrophil activities. These cytokines act on many different cell types and defend against different extracellular pathogens causing fungal or bacterial infections. This product is approved for several indications, such as plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. However, the company is investigating this product in Phase III for the treatment of hidradenitis suppurativa patients. This therapeutic molecule is administered by the subcutaneous route. Data from SUNSHINE and SUNRISE trials were submitted to health authorities as part of regulatory applications. The company expects a regulatory decision in the first half of 2023 in Europe and the second half in 2023 in the US for COSENTYX in hidradenitis suppurativa.

BIMZELX (bimekizumab): UCB Biopharma

Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines, and they are both co-expressed at sites of inflammation and have overlapping pro-inflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. UCB Biopharma has completed the Phase II trial for moderate-to-severe hidradenitis suppurativa. In May 2022, UCB announced that the US FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate-to-severe plaque psoriasis. As per the company, results from two Phase III (BE HEARD I and BE HEARD II) studies will form the basis of global regulatory applications for bimekizumab in hidradenitis suppurativa starting in Q3 2023.

Note: Detailed emerging therapies assessment will be provided in the final report.

Hidradenitis Suppurativa Market Outlook

Hidradenitis Suppurativa (HS) is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas, such as the axilla and groin. The disease is poorly understood, and treatment is not satisfactory.

As there is no cure for Hidradenitis suppurativa, early diagnosis and treatment help prevent the disease from getting worse and forming additional scars, and the current treatment approaches depend on the severity and clinical staging of the disease.

There are a number of lifestyle modifications recommended, such as smoking cessation, weight loss, and stress management, but there is little evidence regarding their efficacy. In terms of pharmacological treatment market options, the following therapies are available like topical and systemic antibiotics, corticosteroids, hormonal therapy, systemic retinoid, zinc supplements, and immunosuppressive agents including biologics (HUMIRA, Infliximab). Other pharmacological therapies like birth control pills (to address the hormonal cause of Hidradenitis suppurativa) can also be used.

The mainstay of medical treatment of mild disease involves anti-bacterial washes and topical antibiotics. Acute flares may be managed by intralesional corticosteroids and/or minor surgical procedures. Oral therapies for mild to moderate Hidradenitis suppurativa include extended courses of broad-spectrum antibiotics and systemic retinoid. Currently, the market is mainly driven by off-label therapies and HUMIRA, as it is the only approved therapy for Hidradenitis suppurativa until now.

In severe cases, the oral combo of clindamycin and rifampicin is effective and is used as a first-line treatment. Other first-line treatments like topical Clindamycin, tetracycline, and subcutaneous Adalimumab (HUMIRA) are also there.

However, HUMIRA is the only officially approved treatment for the management of moderate-to-severe Hidradenitis suppurativa by both the European Medicines Agency (EMA) in June 2015 and the US FDA in September 2015. It is a recombinant, fully humanized, anti-tumor necrosis factor-alpha (anti-TNF-a) monoclonal antibody (IgG1) that has a high affinity and specificity for TNF-a.

Moving forward, in off-label therapies, the commonly used antibiotics are clindamycin, rifampicin, and tetracycline as these antibiotics have shown their efficacy in the studies, and these antibiotics are used when more severe or widely spread lesions are present.

On the other hand, corticosteroids like triamcinolone acetonide have been used for the rapid reduction in inflammation associated with acute flares and for the management of recalcitrant nodules and sinus tracts. Additionally, corticosteroids, such as prednisone, are also used to reduce pain and swelling.

Key Findings

This section includes a glimpse of the Hidradenitis suppurativa in the 7MM market.

• The total market size of Hidradenitis Suppurativa in the US is approximately USD 1,000 million in 2022 and is projected to grow during the forecast period (2023-2032).
• Among EU4 and the UK, Germany had the maximum market share in 2022 while Spain had the lowest market share.
• The market size of Hidradenitis Suppurativa in Japan is approximately USD 5 million in 2022 which is expected to rise during the forecast period (2023-2032).

Analyst Commentary

• Hidradenitis Suppurativa market has diverse pipeline targeting Interleukins (i.e. IL-17, IL-1), anti-TNF, JAK inhibitors and anti-complement factor.
• Pipeline therapies are coming with patient convenient route of administration and also expected to increase the treatment duration.
• Emerging therapies with better clinical profile compared to HUMIRA expected to dominate the market.
• Currently only HUMIRA is approved for the treatment of moderate to severe Hidradenitis suppurativa thus providing the potential lucrative market opportunities.
• No treatment options available in relapsed/ refractory patients to HUMIRA.
• Now companies are also focusing on the development of biomarkers which will further increase the prevalent pool owing to diagnosis in early stages for better diagnosis.
• Rising prevalence of Hidradenitis suppurativa will provide the larger window of opportunity for new treatment.

Hidradenitis Suppurativa Drugs Uptake

This section focusses on the rate of uptake of the potential drugs expected to get launched in the market during the forecast period 2023-2032. The analysis covers Hidradenitis suppurativa market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. We expect the launch of Bimekizumab in 2024, as the company anticipates starting filings from Q3 2023.

Hidradenitis Suppurativa Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Hidradenitis Suppurativa emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders are professors of dermatology, the University of Pennsylvania, Head of the Dermatology Department, Saint Louis Hospital, Paris, Chief Medical Officers. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hidradenitis Suppurativa market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Hidradenitis Suppurativa market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the Hidradenitis Suppurativa epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Hidradenitis Suppurativa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Hidradenitis Suppurativa market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Hidradenitis Suppurativa market.

Report Highlights:

• In the coming years, Hidradenitis Suppurativa market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• The report also encompasses other major segments, i.e., Total diagnosed prevalent cases of Hidradenitis Suppurativa, Gender-specific prevalent cases of Hidradenitis Suppurativa, Age-specific prevalent cases of Hidradenitis Suppurativa, Stage-specific cases of Hidradenitis Suppurativa.
• Expected Launch of potential therapies, COSENTYX (Novartis Pharmaceuticals), BIMZELX (UCB Biopharma) and others might change the landscape in treatment of Hidradenitis Suppurativa.
• The introduction of biosimilars has significantly affected HUMIRA's sales in Europe and Japan.

Hidradenitis Suppurativa Report Insights

Hidradenitis Suppurativa Report Insights

• Patient Population
• Therapeutic Approaches
• Hidradenitis Suppurativa Pipeline Analysis
• Hidradenitis Suppurativa Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Hidradenitis Suppurativa Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Hidradenitis Suppurativa Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Hidradenitis Suppurativa Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT
• Attribute Analysis

Key Questions

Market Insights:

• What was the Hidradenitis Suppurativa market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Hidradenitis Suppurativa total market size as well as market size by therapies across the 7MM during the study period (2019-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Hidradenitis Suppurativa market size during the study period (2019-2032)?
• At what CAGR, the Hidradenitis Suppurativa market is expected to grow at the 7MM level during the study period (2019-2032)?
• What would be the Hidradenitis Suppurativa market outlook across the 7MM during the study period (2019-2032)?
• What would be the Hidradenitis Suppurativa market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden, and unmet needs of Hidradenitis Suppurativa?
• What is the historical Hidradenitis Suppurativa patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the UK and Japan?
• What would be the forecasted patient pool of Hidradenitis Suppurativa at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hidradenitis Suppurativa?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Hidradenitis Suppurativa during the study period (2019-2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Hidradenitis Suppurativa? What are the current treatment guidelines for the treatment of Hidradenitis Suppurativa in the US and Europe?
• What are the Hidradenitis Suppurativa marketed drugs and their MOA, regulatory milestones, product development activities, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Hidradenitis Suppurativa?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Hidradenitis Suppurativa?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Hidradenitis Suppurativa therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hidradenitis Suppurativa and their status?
• What are the key designations that have been granted for the emerging therapies for Hidradenitis Suppurativa?
• What are the 7MM historical and forecasted market of Hidradenitis Suppurativa?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Hidradenitis Suppurativa.
• To understand the future market competition in the Hidradenitis Suppurativa market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Hidradenitis Suppurativa in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Hidradenitis Suppurativa market.
• To understand the future market competition in the Hidradenitis Suppurativa market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Hidradenitis Suppurativa Market Overview at a Glance

• 3.1. Market Share by Therapies (%) Distribution of Hidradenitis Suppurativa in 2019
• 3.2. Market Share by Therapies (%) Distribution of Hidradenitis Suppurativa in 2032

4. Executive Summary of Hidradenitis Suppurativa

5. Key Events

6. Epidemiology and Market Methodology

7. Disease Overview: Hidradenitis Suppurativa

• 7.1. Introduction
• 7.2. Causes and Symptoms of Hidradenitis Suppurativa
• 7.3. Classification and Severity Assessment of Hidradenitis Suppurativa
  • 7.3.1. Hurley Stages of hidradenitis suppurativa
  • 7.3.2. Modified Sartorius Score (MSS) of hidradenitis suppurativa
  • 7.3.3. Physician Global Assessment of Hidradenitis Suppurativa
  • 7.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
• 7.4. Pathophysiology of Hidradenitis Suppurativa
• 7.5. Genetic Basis of Hidradenitis Suppurativa
• 7.6. Diagnosis of Hidradenitis Suppurativa
  • 7.6.1. Differential Diagnoses
• 7.7. Biomarkers of Hidradenitis Suppurativa
• 7.8. Risk Factors and Complications
• 7.9. Comorbidities

8. Treatment and Guidelines

• 8.1. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa: (2015)
  • 8.1.1. Medical therapy
  • 8.1.2. Surgical therapy
• 8.2. North American Clinical Management Guidelines for Hidradenitis Suppurativa: (2019)
  • 8.2.1. Diagnosis, evaluation, and the use of complementary and procedural management
  • 8.2.2. Topical, intralesional, and systemic medical management
• 8.3. British Association of Dermatologists Guidelines for the Management of Hidradenitis Suppurativa (Acne Inversa): (2018)
• 8.4. Guidelines for the Management of Hidradenitis Suppurativa: Recommendations Supported by the Centre of Evidence of the French Society of Dermatology: (2021)
• 8.5. Hidradenitis Suppurativa/Acne Inversa: A Practical Framework for Treatment Optimization - Systematic Review and Recommendations from the Hidradenitis Suppurativa Alliance Working Group: (2018)

9. Epidemiology and Patient Population

• 9.1. Assumptions and Rationale: 7MM
• 9.2. Key Findings
• 9.3. Total Prevalent Cases of Hidradenitis Suppurativa in the 7MM
• 9.4. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the 7MM
• 9.5. The United States
  • 9.5.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States
  • 9.5.2. Gender-Specific Prevalent Cases of Hidradenitis Suppurativa in the United States
  • 9.5.3. Age-specific Prevalent Cases of Hidradenitis Suppurativa in the United States
  • 9.5.4. Stage-specific Prevalent Cases of Hidradenitis Suppurativa in the United States
  • 9.5.5. Treated Prevalent Cases of Hidradenitis Suppurativa in the United States
• 9.6. EU4 and the UK
  • 9.6.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the EU4 and the UK
  • 9.6.2. Gender-specific Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
  • 9.6.3. Age-specific Cases of Hidradenitis Suppurativa in EU4 and the UK
  • 9.6.4. Stage-specific Cases of Hidradenitis Suppurativa in EU4 and the UK
  • 9.6.5. Treated Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan
  • 9.7.2. Gender-specific Prevalent Cases of Hidradenitis Suppurativa in Japan
  • 9.7.3. Age-specific Prevalent Cases of Hidradenitis Suppurativa in Japan
  • 9.7.4. Stage-specific Prevalent Cases of Hidradenitis Suppurativa in Japan
  • 9.7.5. Treated Prevalent Cases of hidradenitis suppurativa in Japan

10. Patient Journey of Hidradenitis Suppurativa

11. Key Endpoints in Hidradenitis Suppurativa Clinical Trials

12. Marketed Drug

• 12.1. HUMIRA: AbbVie
  • 12.1.1. Product description
  • 12.1.2. Regulatory milestones
  • 12.1.3. Other developmental activities
  • 12.1.4. Pivotal clinical trials
    • 12.1.4.1. Summary of pivotal clinical trials
  • 12.1.5. Product profile

13. Emerging Drugs

• 13.1. Key Cross
• 13.3. COSENTYX (secukinumab): Novartis Pharmaceuticals
  • 13.3.1. Product description
  • 13.3.2. Other developmental activities
  • 13.3.3. Clinical development
    • 13.3.3.1. Clinical trial information
  • 13.3.4. Safety and efficacy
• 13.4. BIMZELX (bimekizumab): UCB Biopharma
  • 13.4.1. Product description
  • 13.4.2. Other developmental Activities
  • 13.4.3. Clinical development
    • 13.4.3.1. Clinical trials information
  • 13.4.4. Safety and efficacy
• 13.5. Povorcitinib (INCB054707): Incyte Corporation
  • 13.5.1. Product description
  • 13.5.2. Clinical development
    • 13.5.2.1. Clinical trials information
  • 13.5.3. Safety and efficacy
• 13.6. Ruxolitinib 1.5% Cream: Incyte Corporation
  • 13.6.1. Product description
  • 13.6.2. Other developmental activity
  • 13.6.3. Clinical development
    • 13.6.3.1. Clinical trial information
• 13.7. CFZ533 (Iscalimab), LYS006, LOU064 and MAS825: Novartis Pharmaceuticals
  • 13.7.1. Product description
  • 13.7.2. Other developmental activities
  • 13.7.3. Clinical development
    • 13.7.3.1. Clinical trials information
• 13.8. Lutikizumab (ABT-981): AbbVie
  • 13.8.1. Product description
  • 13.8.2. Other developmental activity
  • 13.8.3. Clinical development
    • 13.8.3.1. Clinical trial information
• 13.9. Zunsemetinib: Aclaris Therapeutics
  • 13.9.1. Product description
  • 13.9.2. Clinical development
    • 13.9.2.1. Clinical trial information
  • 13.9.3. Safety and efficacy
• 13.10. Spesolimab: Boehringer Ingelheim
  • 13.10.1. Product description
  • 13.10.2. Clinical development
    • 13.10.2.1. Clinical trials information
  • 13.10.3. Safety and efficacy
• 13.11. Orismilast: UNION Therapeutics
  • 13.11.1. Product description
  • 13.11.2. Other developmental activities
  • 13.11.3. Clinical development
    • 13.11.3.1. Clinical trials information
  • 13.11.4. Safety and efficacy
• 13.12. RINVOQ (upadacitinib): AbbVie
  • 13.12.1. Product description
  • 13.12.2. Other developmental activities
  • 13.12.3. Clinical development
    • 13.12.3.1. Clinical trials information
  • 13.12.4. Safety and efficacy
• 13.13. Izokibep: ACELYRIN
  • 13.13.1. Product description
  • 13.13.2. Other developmental Activities
  • 13.13.3. Clinical development
    • 13.13.3.1. Clinical trials information
  • 13.13.4. Safety and efficacy
• 13.14. Brepocitinib (PF-06700841): Priovant Therapeutics/Pfizer
  • 13.14.1. Product description
  • 13.14.2. Clinical development
    • 13.14.2.1. Clinical Trial Information
  • 13.14.3. Safety and Efficacy
• 13.15. Sonelokimab (M1095): MoonLake Immunotherapeutics
  • 13.15.1. Product description
  • 13.15.2. Other developmental activity
  • 13.15.3. Clinical development
    • 13.15.3.1. Clinical trial information
• 13.16. Eltrekibart (LY3041658): Eli Lilly
  • 13.16.1. Product description
  • 13.16.2. Clinical development
    • 13.16.2.1. Clinical trial information
  • 13.16.3. Safety and efficacy

14. Hidradenitis Suppurativa: Seven Major Market Analysis

• 14.1. Key Findings
• 14.2. Market Outlook
• 14.3. Conjoint Analysis
• 14.4. Key Market Forecast Assumptions
• 14.5. Total Market Size of Hidradenitis Suppurativa in the 7MM
• 14.6. United States Market Size
  • 14.6.1. Total Market Size of Hidradenitis Suppurativa in the United States
  • 14.6.2. Market Size of Hidradenitis Suppurativa by Therapies in the United States
• 14.7. EU4 and the UK Market Size
  • 14.7.1. Total market size of hidradenitis suppurativa in EU4 and the UK
  • 14.7.2. Market size of hidradenitis suppurativa by therapies in EU4 and the UK
• 14.8. Japan
  • 14.8.1. Total market size of hidradenitis suppurativa in Japan
  • 14.8.2. Market size of hidradenitis suppurativa by therapies in Japan

15. Market Access and Reimbursement

• 15.1. NICE UK
• 15.2. Ministry of Health and Solidarity (DRESS) (France)
• 15.3. Co-payment in the European Countries
• 15.4. HUMIRA Reimbursement Program

16. Unmet Needs

17. SWOT Analysis

18. KOL Views

19. Appendix

• 19.1. Bibliography
• 19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight